Lipocine Inc. 8-K

What Happened
Lipocine Inc. (LPCN) filed an 8-K on January 12, 2026 to report that it issued a press release announcing "encouraging progress" following the second interim safety review in its Phase 3 clinical trial of LPCN 1154 for postpartum depression. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 8.01 — Other Events).
• Program: Phase 3 trial of LPCN 1154 targeting postpartum depression.
• Milestone: Company reported encouraging progress following the second interim safety review (no efficacy or enrollment numbers disclosed in the 8-K).
• Disclosure: Press release provided as Exhibit 99.1 to the filing.

Why It Matters
The update confirms Lipocine is actively advancing its Phase 3 program and that a planned interim safety review has not produced a setback significant enough to halt or terminate the trial (the company described progress as "encouraging"). For investors, this is a development milestone for a late‑stage clinical asset; however, the 8-K contains limited detail (no safety data, efficacy results, timelines, or enrollment figures). Watch for follow-up releases or regulatory disclosures that provide concrete safety outcomes, efficacy data, or changes to expected timelines that could more directly affect the company's clinical and commercial prospects.